(redirected from Unresectable Hepatocellular Carcinoma)
uHCCUnresectable Hepatocellular Carcinoma (oncology)
uHCCUniversity of Hawaii Cancer Center (Honolulu, HI)
uHCCUpper Hutt City Council (New Zealand)
uHCCUniversity of Hawai'i Community Colleges
uHCCUnion of Health Care Committees
uHCCUniversity Heights Community Center
uHCCUniversity Health Care Center
uHCCUnion of Hellenic Chambers of Commerce
uHCCUluru Health Care Centre
uHCCUnited Hindu Cultural Council
uHCCUV Honey Comb Cuff
uHCCUbly Heights Country Club (Ubly, Michigan)
uHCCUniversity of Huddersfield Climbing Club (UK)
uHCCUnited Hindu Congress Canada (Toronto, Ontario, Canada)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
The data from this single site at the Peking University Cancer Hospital and Institute in Beijing show an overall survival improvement of 22.5 months in patients with 3-7 cm unresectable hepatocellular carcinoma tumors receiving combined radiofrequency ablation and ThermoDox, compared with the use of RFA alone.
Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for LENVIMA, the orally available kinase inhibitor discovered by Eisai, in combination with KEYTRUDA, Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s anti-PD-1 therapy, for the potential first-line treatment of patients with advanced unresectable hepatocellular carcinoma (HCC) not amenable to locoregional treatment.
For LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination Treatment as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment
Eisai Co Ltd, a Japan-based pharmaceutical company and Merck +ACY- Co Inc, based in Kenilworth NJ, USA, known as MSD outside of the United States and Canada, announced yesterday that the European Commission (EC) has granted a marketing authorisation for the oral receptor tyrosine kinase (RTK) inhibitor LENVIMA(R) (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
This US FDA approval was based on results from the company's REFLECT (Study 304), a large phase 3, randomized, multicenter, open-label trial conducted by Eisai to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in patients with unresectable hepatocellular carcinoma (HCC).
Nexavar[R] Tablets 200 mg (Nonproprietary Name: Sorafenib Tosylate Tablets) specific drug use investigation for unresectable hepatocellular carcinoma. Osaka: Bayer Yakuhin Ltd; 2016.
Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011: D4787.
Federle, "Chemoembolization for unresectable hepatocellular carcinoma in patients with or without portal vein thrombosis," Hepato-Gastroenterology, vol.
Transarterial chemoembolization (TACE) is the first-line therapy for patients with an unresectable hepatocellular carcinoma (HCC) and hepatic metastases.
Bruix, "Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival," Hepatology, vol.
The great importance of such knowledge lies in the fact that an unresectable hepatocellular carcinoma can be treated by transcatheter embolization of not only its typical blood supply, the right or left hepatic arteries, but also by embolization of a right inferior phrenic artery, if involved.